SG11201806700RA - Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof - Google Patents
Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereofInfo
- Publication number
- SG11201806700RA SG11201806700RA SG11201806700RA SG11201806700RA SG11201806700RA SG 11201806700R A SG11201806700R A SG 11201806700RA SG 11201806700R A SG11201806700R A SG 11201806700RA SG 11201806700R A SG11201806700R A SG 11201806700RA SG 11201806700R A SG11201806700R A SG 11201806700RA
- Authority
- SG
- Singapore
- Prior art keywords
- nsw
- road
- co7d
- international
- frenchs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/42—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 August 2017 (17.08.2017) WiP0 I PCT 111111111111011010101111101011111 0 01110011011104011011101110# (10) International Publication Number WO 2017/136870 A9 (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/404 (2006.01) CO7D 413/04 (2006.01) A61P 1/16 (2006.01) CO7D 405/04 (2006.01) A61P 9/00 (2006.01) CO7D 403/04 (2006.01) A61P 13/12 (2006.01) CO7D 401/04 (2006.01) A61P 29/00 (2006.01) CO7D 209/10 (2006.01) A61P 35/00 (2006.01) A61K 31/33 (2006.01) (21) International Application Number: PCT/AU2017/000039 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016900478 12 February 2016 (12.02.2016) AU 2016902593 01 July 2016 (01.07.2016) AU (71) Applicant: PHARMAXIS LTD. [AU/AU]; 20 Rodbor- ough Road, Frenchs Forest, NSW 2086 (AU). (72) Inventors: FINDLAY, Alison Dorothy; 20 Rodbor- ough Road, Frenchs Forest, NSW 2086 (AU). TURN- ER, Craig Ivan; 20 Rodborough Road, Frenchs For- est, NSW 2086 (AU). DEODHAR, Mandar; 20 Rod- borough Road, Frenchs Forest, NSW 2086 (AU). FOOT, Jonathan Stuart; 20 Rodborough Road, Frenchs Forest, NSW 2086 (AU). JAROLIMEK, Wolfgang; 20 Rodbor- ough Road, Frenchs Forest, NSW 2086 (AU). ZHOU, Wenbin; 20 Rodborough Road, Frenchs Forest, NSW 2086 (AU). ROBERTSON, Alan Duncan; 12 Cherry Street, Warrawee, NSW 2074 (AU). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (48) Date of publication of this corrected version: 15 February 2018 (15.02.2018) (15) Information about Correction: see Notice of 15 February 2018 (15.02.2018) W O 20 17 / 13687 0 A9 (74) Agent: SPRUSON & FERGUSON; GPO Box 3898, Syd- ney, New South Wales 2001 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF (57) : The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016900478A AU2016900478A0 (en) | 2016-02-12 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
AU2016902593A AU2016902593A0 (en) | 2016-07-01 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
PCT/AU2017/000039 WO2017136870A1 (en) | 2016-02-12 | 2017-02-10 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806700RA true SG11201806700RA (en) | 2018-09-27 |
Family
ID=59562850
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806700RA SG11201806700RA (en) | 2016-02-12 | 2017-02-10 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
SG11201806727TA SG11201806727TA (en) | 2016-02-12 | 2017-02-10 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806727TA SG11201806727TA (en) | 2016-02-12 | 2017-02-10 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (3) | US10717733B2 (en) |
EP (2) | EP3414244A4 (en) |
JP (2) | JP6843888B2 (en) |
KR (2) | KR20180134849A (en) |
CN (2) | CN109071533B (en) |
AU (2) | AU2017217239A1 (en) |
BR (2) | BR112018067442A8 (en) |
CA (2) | CA3013850C (en) |
CO (2) | CO2018009071A2 (en) |
EA (2) | EA201891674A1 (en) |
IL (2) | IL261119B (en) |
MX (1) | MX2018009645A (en) |
PH (2) | PH12018501686A1 (en) |
SG (2) | SG11201806700RA (en) |
TW (2) | TW201739454A (en) |
WO (2) | WO2017136870A1 (en) |
ZA (2) | ZA201805664B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10717733B2 (en) | 2016-02-12 | 2020-07-21 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
CN110709385A (en) * | 2017-03-02 | 2020-01-17 | 法玛西斯有限公司 | Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof |
CN107903281B (en) * | 2017-10-27 | 2019-10-29 | 苏州大学 | A kind of method of synthesis of alkyl boron ester compounds |
AR117398A1 (en) | 2018-03-12 | 2021-08-04 | Abbvie Inc | INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE 2 |
KR20190110740A (en) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | Novel aryl or heteroaryl triazolone derivatives or its salt and pharmaceutical compositions comprising the same |
KR20190110736A (en) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | Novel triazolone derivatives or its salt and pharmaceutical compositions comprising the same |
JP7414803B2 (en) | 2018-08-03 | 2024-01-16 | ファーマクシス リミテッド | Haloallylamine sulfone derivative inhibitors of lysyl oxidase and their use |
MX2021007069A (en) | 2018-12-14 | 2021-10-01 | Yuhan Corp | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same. |
TW202039486A (en) | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same |
WO2020146639A2 (en) * | 2019-01-11 | 2020-07-16 | Viscient Biosciences, Inc. | Compositions and methods for the diagnosis and treatment of diseases of the liver |
WO2020161208A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
WO2020161209A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
BR112022000782A2 (en) * | 2019-07-25 | 2022-03-15 | Pharmaxis Ltd | Compound, pharmaceutical composition, process for preparing a compound, intermediate compound, and, use of a compound, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition |
KR20220046584A (en) | 2019-07-29 | 2022-04-14 | 헤파레게닉스 게엠베하 | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocellular death |
CA3164361A1 (en) | 2020-01-15 | 2021-07-22 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
WO2021155439A1 (en) * | 2020-02-05 | 2021-08-12 | Pharmaxis Ltd. | Bioprobes for lysyl oxidases and uses thereof |
KR20230031285A (en) | 2020-06-26 | 2023-03-07 | 라퀄리아 파마 인코포레이티드 | Method for selecting cancer patients for which combination therapy of retinoid and cancer drug is effective and combination medicine of retinoid and cancer drug |
JP7384138B2 (en) | 2020-09-30 | 2023-11-21 | 株式会社島津製作所 | electrophoresis device |
KR20230047910A (en) * | 2021-10-01 | 2023-04-10 | 주식회사유한양행 | Bicyclic fused-ring derivatives or a salt thereof and pharmaceutical compositions comprising the same |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4699928A (en) | 1984-07-13 | 1987-10-13 | Merrell Dow Pharmaceuticals Inc. | Fluoroallylamine derivatives |
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4943593A (en) * | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US9161922B2 (en) * | 2005-07-01 | 2015-10-20 | Case Western Reserve University | Amine oxidase inhibitors |
EP2004166A2 (en) | 2006-03-31 | 2008-12-24 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
US20080293936A1 (en) * | 2007-05-23 | 2008-11-27 | Elmar Reinhold Burchardt | Novel inhibitors of lysyl oxidase |
AU2014200520A1 (en) * | 2007-08-02 | 2014-02-20 | Gilead Biologics, Inc. | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
JP5659014B2 (en) | 2007-08-02 | 2015-01-28 | ジリード バイオロジクス,インク. | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis and metastasis |
JP2011503103A (en) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | Methods for regulating protein transport |
CA2706465A1 (en) | 2007-11-21 | 2009-05-28 | Pharmaxis Ltd. | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
CA2755768A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
WO2011022670A1 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
SI2844637T1 (en) | 2012-05-02 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
RU2732416C2 (en) * | 2014-07-31 | 2020-09-16 | Институт Пастер Корея | 2-amino-benzimidazole derivatives and use thereof as 5-lipoxygenase and/or prostaglandin e-synthase inhibitors |
US10717733B2 (en) | 2016-02-12 | 2020-07-21 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
-
2017
- 2017-02-10 US US16/076,979 patent/US10717733B2/en active Active
- 2017-02-10 CA CA3013850A patent/CA3013850C/en active Active
- 2017-02-10 SG SG11201806700RA patent/SG11201806700RA/en unknown
- 2017-02-10 JP JP2018561293A patent/JP6843888B2/en active Active
- 2017-02-10 WO PCT/AU2017/000039 patent/WO2017136870A1/en active Application Filing
- 2017-02-10 BR BR112018067442A patent/BR112018067442A8/en not_active Application Discontinuation
- 2017-02-10 SG SG11201806727TA patent/SG11201806727TA/en unknown
- 2017-02-10 KR KR1020187024805A patent/KR20180134849A/en active Search and Examination
- 2017-02-10 KR KR1020187024804A patent/KR20180119582A/en unknown
- 2017-02-10 AU AU2017217239A patent/AU2017217239A1/en not_active Abandoned
- 2017-02-10 EP EP17749812.8A patent/EP3414244A4/en active Pending
- 2017-02-10 CN CN201780019641.3A patent/CN109071533B/en active Active
- 2017-02-10 AU AU2017217238A patent/AU2017217238B2/en active Active
- 2017-02-10 WO PCT/AU2017/000040 patent/WO2017136871A1/en active Application Filing
- 2017-02-10 EP EP17749813.6A patent/EP3414226A4/en active Pending
- 2017-02-10 EA EA201891674A patent/EA201891674A1/en unknown
- 2017-02-10 MX MX2018009645A patent/MX2018009645A/en unknown
- 2017-02-10 US US16/076,985 patent/US10717734B2/en active Active
- 2017-02-10 JP JP2018561294A patent/JP6849197B2/en active Active
- 2017-02-10 CN CN201780019653.6A patent/CN109153642B/en active Active
- 2017-02-10 EA EA201891676A patent/EA037302B9/en unknown
- 2017-02-10 BR BR112018016484-4A patent/BR112018016484B1/en active IP Right Grant
- 2017-02-10 CA CA3013819A patent/CA3013819A1/en not_active Abandoned
- 2017-02-13 TW TW106104662A patent/TW201739454A/en unknown
- 2017-02-13 TW TW106104664A patent/TW201738206A/en unknown
-
2018
- 2018-08-07 PH PH12018501686A patent/PH12018501686A1/en unknown
- 2018-08-07 PH PH12018501685A patent/PH12018501685A1/en unknown
- 2018-08-12 IL IL261119A patent/IL261119B/en unknown
- 2018-08-12 IL IL261118A patent/IL261118A/en unknown
- 2018-08-24 ZA ZA2018/05664A patent/ZA201805664B/en unknown
- 2018-08-24 ZA ZA2018/05675A patent/ZA201805675B/en unknown
- 2018-08-28 CO CONC2018/0009071A patent/CO2018009071A2/en unknown
- 2018-08-28 CO CONC2018/0009068A patent/CO2018009068A2/en unknown
-
2020
- 2020-06-11 US US16/899,116 patent/US11098045B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806700RA (en) | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201900545TA (en) | Pharmaceutical compounds | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |